1
|
Miller N, Xu Z, Quinlan KA, Ji A, McGivern JV, Feng Z, Shi H, Ko CP, Tsai LH, Heckman CJ, Ebert AD, Ma YC. Mitigating aberrant Cdk5 activation alleviates mitochondrial defects and motor neuron disease symptoms in spinal muscular atrophy. Proc Natl Acad Sci U S A 2023; 120:e2300308120. [PMID: 37976261 PMCID: PMC10666147 DOI: 10.1073/pnas.2300308120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 07/31/2023] [Indexed: 11/19/2023] Open
Abstract
Spinal muscular atrophy (SMA), the top genetic cause of infant mortality, is characterized by motor neuron degeneration. Mechanisms underlying SMA pathogenesis remain largely unknown. Here, we report that the activity of cyclin-dependent kinase 5 (Cdk5) and the conversion of its activating subunit p35 to the more potent activator p25 are significantly up-regulated in mouse models and human induced pluripotent stem cell (iPSC) models of SMA. The increase of Cdk5 activity occurs before the onset of SMA phenotypes, suggesting that it may be an initiator of the disease. Importantly, aberrant Cdk5 activation causes mitochondrial defects and motor neuron degeneration, as the genetic knockout of p35 in an SMA mouse model rescues mitochondrial transport and fragmentation defects, and alleviates SMA phenotypes including motor neuron hyperexcitability, loss of excitatory synapses, neuromuscular junction denervation, and motor neuron degeneration. Inhibition of the Cdk5 signaling pathway reduces the degeneration of motor neurons derived from SMA mice and human SMA iPSCs. Altogether, our studies reveal a critical role for the aberrant activation of Cdk5 in SMA pathogenesis and suggest a potential target for therapeutic intervention.
Collapse
Affiliation(s)
- Nimrod Miller
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL60611
| | - Zhaofa Xu
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL60611
| | - Katharina A. Quinlan
- Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Department of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI02881
| | - Amy Ji
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL60611
| | - Jered V. McGivern
- Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI53226
| | - Zhihua Feng
- Section of Neurobiology, Department of Biological Sciences, University of Southern California, Los Angeles, CA90089
| | - Han Shi
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL60611
| | - Chien-Ping Ko
- Section of Neurobiology, Department of Biological Sciences, University of Southern California, Los Angeles, CA90089
| | - Li-Huei Tsai
- Department of Brain and Cognitive Sciences, Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA02139
| | - Charles J. Heckman
- Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Department of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL60611
| | - Allison D. Ebert
- Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI53226
| | - Yongchao C. Ma
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL60611
- Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL60611
- Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL60611
| |
Collapse
|
2
|
Turer R, Champion J, Rothman B, Dunn H, Jenkins K, Evernham O, Barrett T, Jones I, Miller N. 69 Improving Critical Care Documentation in an Academic Emergency Department via Point-of-Documentation Decision Support. Ann Emerg Med 2022. [DOI: 10.1016/j.annemergmed.2022.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Patel M, Williams J, Bachman M, Cyr J, Cabanas J, Miller N, Gorstein L, Turcios H, Malcolm JT, Brice J. 406EMF Early Fluid Delivery by Emergency Medical Services for Sepsis Using a Novel Rapid Infusion Device. Ann Emerg Med 2022. [DOI: 10.1016/j.annemergmed.2022.08.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L, Gath J, Kennedy F, Martin C, Wyld L, Fisher A. An app with brief behavioural support to promote physical activity after a cancer diagnosis (APPROACH): study protocol for a pilot randomised controlled trial. Pilot Feasibility Stud 2022; 8:74. [PMID: 35351187 PMCID: PMC8961486 DOI: 10.1186/s40814-022-01028-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 03/09/2022] [Indexed: 11/22/2022] Open
Abstract
Background There are multiple health benefits from participating in physical activity after a cancer diagnosis, but many people living with and beyond cancer (LWBC) are not meeting physical activity guidelines. App-based interventions offer a promising platform for intervention delivery. This trial aims to pilot a theory-driven, app-based intervention that promotes brisk walking among people living with and beyond cancer. The primary aim is to investigate the feasibility and acceptability of study procedures before conducting a larger randomised controlled trial (RCT). Methods This is an individually randomised, two-armed pilot RCT. Patients with localised or metastatic breast, prostate, or colorectal cancer, who are aged 16 years or over, will be recruited from a single hospital site in South Yorkshire in the UK. The intervention includes an app designed to encourage brisk walking (Active 10) supplemented with habit-based behavioural support in the form of two brief telephone/video calls, an information leaflet, and walking planners. The primary outcomes will be feasibility and acceptability of the study procedures. Demographic and medical characteristics will be collected at baseline, through self-report and hospital records. Secondary outcomes for the pilot (assessed at 0 and 3 months) will be accelerometer measured and self-reported physical activity, body mass index (BMI) and waist circumference, and patient-reported outcomes of quality of life, fatigue, sleep, anxiety, depression, self-efficacy, and habit strength for walking. Qualitative interviews will explore experiences of participating or reasons for declining to participate. Parameters for the intended primary outcome measure (accelerometer measured average daily minutes of brisk walking (≥ 100 steps/min)) will inform a sample size calculation for the future RCT and a preliminary economic evaluation will be conducted. Discussion This pilot study will inform the design of a larger RCT to investigate the efficacy and cost-effectiveness of this intervention in people LWBC. Trial registration ISRCTN registry, ISRCTN18063498. Registered 16 April 2021. Supplementary Information The online version contains supplementary material available at 10.1186/s40814-022-01028-w.
Collapse
Affiliation(s)
- P Lally
- Behavioural Science and Health, UCL, Gower Street, London, WC1E 6BT, UK.
| | - N Miller
- Behavioural Science and Health, UCL, Gower Street, London, WC1E 6BT, UK
| | - A Roberts
- Behavioural Science and Health, UCL, Gower Street, London, WC1E 6BT, UK
| | - R J Beeken
- Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | - D M Greenfield
- Sheffield Teaching Hospitals NHS FT, Weston Park Hospital, Sheffield, S10 2SJ, UK
| | - H W W Potts
- Institute of Health Informatics, University College London, London, UK
| | - N Counsell
- Cancer Research UK & UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK
| | - N Latimer
- School of Health and Related Research, University of Sheffield, Sheffield, S1 4DA, UK
| | - C Thomas
- School of Health and Related Research, University of Sheffield, Sheffield, S1 4DA, UK
| | - L Smith
- The Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, CB1 1PT, UK
| | - J Gath
- Yorkshire and Humberside Consumer Research Panel
| | - F Kennedy
- Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | - C Martin
- Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | - L Wyld
- Department of Oncology and Metabolism, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
| | - A Fisher
- Behavioural Science and Health, UCL, Gower Street, London, WC1E 6BT, UK
| |
Collapse
|
5
|
Severson P, Kellner W, Franovic A, Miller N, Murphy E, Martin E, Williams R. 40P Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.01.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Marsden D, Miller VR, Chettiath T, Johnson B, Sarafrazi S, Willcock A, Miller N. METABOLIC MYOPATHIES. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Miller N, Pasternak Y, Dornstein C, Haiki. Herzberger E, Zada N, Hemi R, Wiser A. P–640 High physical activity and ovarian reserve: A prospective study of normo-ovulatory professional athletes. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Is high physical activity (HPA) associated with low ovarian reserve in normo-ovulatory, reproductive-age women?
Summary answer
HPA does not affect ovarian reserve negatively.
What is known already
HPA is associated with menstrual irregularities and subsequent potential infertility, probably through hypothalamic neuroendocrine pathways. However, it is not yet known whether HPA influences the ovarian reserves of normo-ovulatory, reproductive-age women.
Study design, size, duration
This observational, cross-sectional study compared 30 professional female athletes who were engaged in HPA for at least 3 years prior to study recruitment, with high International Physical Activity Questionnaire (IPAQ) scores and 30 women who did not engage in physical activity. The study was conducted at a tertiary medical center from 2017–2020.
Participants/materials, setting, methods
Physically active, normo-ovulatory women (n = 30), ages 20–35 years were recruited from The Wingate Institute, the Israeli National Institute for Sport Excellence. Non-physically active women (n = 30), matched by age and BMI to the HPA group, were recruited from the hospital staff. Both groups were evaluated for ovarian reserve markers on day 2–5 of the menstrual cycle, including follicular stimulating hormone (FSH), antral follicle count (AFC), anti-Mullerian hormone (AMH) and Inhibin B.
Main results and the role of chance
The average age of the athletes (HPA group) was 30.1±2.1 years and of the nonactive (control) group 31.6±3.8 years (p = 0.071). BMI of the 2 groups was similar (22.6±2.4 vs. 21.3±2.6; p = 0.075) for the HPA and control groups, respectively. Regarding ovarian reserve, no significant differences were observed between the HPA group and the control group with respect to FSH (p = 0.304), AFC (p = 0.27), AMH (0.507) or Inhibin B (p = 0.074). For the HPA group, older age at menarche was positively associated with AFC (p = 0.008) and AMH (p = 0.009) and not with FSH levels (p = 0.313). For the nonactive group, no significant association between age at menarche and FSH levels, AFC or AMH was found (p = 0.433, p = 0.274 and p = 0.163, respectively). Additionally, for the HPA group, duration of physical activity per week (hours) was not significantly associated with FSH levels, AFC or AMH (p = 0.619, p = 0.608 or p = 0.997, respectively).
Limitations, reasons for caution
Although we investigated the ovarian reserves of 30 women engaged in HPA, a larger cohort would provide more information. Information on diet and sleep habits was not evaluated and may result in some confounding. Moreover, it would be more informative if we also followed these women regarding fecundability and fertility.
Wider implications of the findings: This study demonstrated that HPA may not negatively affect ovarian reserve markers. These findings may provide reassurance for women who are engaged in HPA and attempting pregnancy. Further research needs s to be confuted.
Trial registration number
0247–16
Collapse
Affiliation(s)
- N Miller
- Meir Medical Center, OB/GYN, Kfar Saba, Israel
| | - Y Pasternak
- Meir Medical Center, OB/GYN, Kfar Saba, Israel
| | - C Dornstein
- Tel Aviv University, Tel Aviv university, Tel Aviv, Israel
| | | | - N Zada
- Sheba Medical Center, Endocrinology Labs, Ramat Gan, Israel
| | - R Hemi
- Sheba Medical Center, Endocrinology Labs, Ramat Gan, Israel
| | - A Wiser
- Meir Medical Center, OB/GYN, Kfar Saba, Israel
| |
Collapse
|
8
|
Davey MG, Ryan ÉJ, Davey MS, Lowery AJ, Miller N, Kerin MJ. Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis. Br J Surg 2021; 108:622-631. [PMID: 33963374 PMCID: PMC10364926 DOI: 10.1093/bjs/znab103] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 01/06/2021] [Accepted: 02/25/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Uncertainty exists regarding the clinical relevance of programmed cell death ligand 1 (PD-L1) expression in breast cancer. METHODS A systematic review was performed in accordance with PRISMA guidelines. Observational studies that compared high versus low expression of PD-L1 on breast cancer cells were identified. Log hazard ratios (HRs) for disease-free and overall survival and their standard errors were calculated from Kaplan-Meier curves or Cox regression analyses, and pooled using the inverse-variance method. Dichotomous variables were pooled as odds ratios (ORs) using the Mantel-Haenszel method. RESULTS Sixty-five studies with 19 870 patients were included; 14 404 patients were classified as having low and 4975 high PD-L1 expression. High PD-L1 was associated with achieving a pathological complete response following neoadjuvant chemotherapy (OR 3.30, 95 per cent confidence interval 1.19 to 9.16; P < 0.01; I2 = 85 per cent). Low PD-L1 expression was associated with human epidermal growth factor receptor 2 (OR 3.98, 1.81 to 8.75; P < 0.001; I2 = 96 per cent) and luminal (OR 14.93, 6.46 to 34.51; P < 0.001; I2 = 99 per cent) breast cancer subtypes. Those with low PD-L1 had favourable overall survival rates (HR 1.30, 1.05 to 1.61; P = 0.02; I2 = 85 per cent). CONCLUSION Breast cancers with high PD-L1 expression are associated with aggressive clinicopathological and immunohistochemical characteristics and are more likely to achieve a pathological complete response following neoadjuvant chemotherapy. These breast cancers are, however, associated with worse overall survival outcomes.
Collapse
Affiliation(s)
- M G Davey
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.,Department of Surgery, Galway University Hospitals, Galway, Ireland
| | - É J Ryan
- Department of Surgery, Galway University Hospitals, Galway, Ireland.,Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - M S Davey
- Department of Surgery, Galway University Hospitals, Galway, Ireland.,Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - A J Lowery
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.,Department of Surgery, Galway University Hospitals, Galway, Ireland
| | - N Miller
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.,Department of Surgery, Galway University Hospitals, Galway, Ireland
| | - M J Kerin
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.,Department of Surgery, Galway University Hospitals, Galway, Ireland
| |
Collapse
|
9
|
Waldron RM, Moloney BM, Gilligan K, Lowery AJ, Joyce MR, Holian E, Kerin MJ, Miller N. MicroRNAs as biomarkers of multimodal treatment for rectal cancer. Br J Surg 2021; 108:e260-e261. [PMID: 33880499 DOI: 10.1093/bjs/znab111] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 01/13/2021] [Accepted: 02/28/2021] [Indexed: 01/27/2023]
Affiliation(s)
- R M Waldron
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - B M Moloney
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - K Gilligan
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - A J Lowery
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - M R Joyce
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - E Holian
- School of Mathematics, Statistics and Applied Mathematics, National University of Ireland, Galway, Ireland
| | - M J Kerin
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - N Miller
- Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| |
Collapse
|
10
|
Bauml J, Mick R, Mccoach C, Weiss J, Marrone K, Nieva J, Villaruz L, Levy B, Moreno R, Murkherji R, Sun F, Schwartzman W, Shaverdashvili K, Wang X, Shah M, Woodley J, Miller N, Succe C, Ullah T, Lovly C, Doebele R, Iams W, Horn L, Dowell J, Liu G, Leighl N, Patil T, Liu S, Velcheti V, Aisner D, Camidge R. FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Ryan ÉB, Yan J, Miller N, Dayanidhi S, Ma YC, Deng HX, Siddique T. Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology. iScience 2021; 24:102061. [PMID: 33659869 PMCID: PMC7890413 DOI: 10.1016/j.isci.2021.102061] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 08/27/2020] [Accepted: 01/12/2021] [Indexed: 12/14/2022] Open
Abstract
Mutations in coiled-coil-helix-coiled-coil-helix domain containing 10 (CHCHD10) have been identified in patients suffering from various degenerative diseases including mitochondrial myopathy, spinal muscular atrophy Jokela type, frontotemporal dementia, and/or amyotrophic lateral sclerosis (ALS). The pathogenic mechanism underlying CHCHD10-linked divergent disorders remains largely unknown. Here we show that transgenic mice overexpressing an ALS-linked CHCHD10 p.R15L mutation leads to an abbreviated lifespan compared with CHCHD10-WT transgenic mice. The occurrence and severity of the phenotype correlates to transgene copy number. Central nervous system (CNS), skeletal muscle, and cardiac pathology is apparent in CHCHD10-R15L transgenic mice. Despite the pathology, CHCHD10-R15L transgenic mice perform comparably to control mice in motor behavioral tasks until very close to death. Although paralysis is not observed, these models provide insight into the pleiotropic nature of CHCHD10 and suggest a contribution of CNS, skeletal muscle, and cardiac pathology to CHCHD10 p.R15L-ALS pathogenesis.
Collapse
Affiliation(s)
- Éanna B. Ryan
- The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Tarry Building, Room 13-715, 303 East Chicago Avenue, Chicago, IL 60611, USA
- Northwestern University Interdepartmental Neuroscience Program, Chicago, IL, USA
| | - Jianhua Yan
- The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Tarry Building, Room 13-715, 303 East Chicago Avenue, Chicago, IL 60611, USA
| | - Nimrod Miller
- Ann and Robert H. Lurie Children's Hospital of Chicago and Departments of Pediatrics, Neurology and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Sudarshan Dayanidhi
- Shirley Ryan AbilityLab and Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Yongchao C. Ma
- Ann and Robert H. Lurie Children's Hospital of Chicago and Departments of Pediatrics, Neurology and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Han-Xiang Deng
- The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Tarry Building, Room 13-715, 303 East Chicago Avenue, Chicago, IL 60611, USA
| | - Teepu Siddique
- The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Tarry Building, Room 13-715, 303 East Chicago Avenue, Chicago, IL 60611, USA
- Northwestern University Interdepartmental Neuroscience Program, Chicago, IL, USA
- Department of Cell and Developmental Biology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
12
|
Bogema DR, McKinnon J, Liu M, Hitchick N, Miller N, Venturini C, Iredell J, Darling AE, Roy Chowdury P, Djordjevic SP. Whole-genome analysis of extraintestinal Escherichia coli sequence type 73 from a single hospital over a 2 year period identified different circulating clonal groups. Microb Genom 2020; 6. [PMID: 30810518 PMCID: PMC7067039 DOI: 10.1099/mgen.0.000255] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Sequence type (ST)73 has emerged as one of the most frequently isolated extraintestinal pathogenic Escherichia coli. To examine the localized diversity of ST73 clonal groups, including their mobile genetic element profile, we sequenced the genomes of 16 multiple-drug resistant ST73 isolates from patients with urinary tract infection from a single hospital in Sydney, Australia, between 2009 and 2011. Genome sequences were used to generate a SNP-based phylogenetic tree to determine the relationship of these isolates in a global context with ST73 sequences (n=210) from public databases. There was no evidence of a dominant outbreak strain of ST73 in patients from this hospital, rather we identified at least eight separate groups, several of which reoccurred, over a 2 year period. The inferred phylogeny of all ST73 strains (n=226) including the ST73 clone D i2 reference genome shows high bootstrap support and clusters into four major groups that correlate with serotype. The Sydney ST73 strains carry a wide variety of virulence-associated genes, but the presence of iss, pic and several iron-acquisition operons was notable.
Collapse
Affiliation(s)
- D R Bogema
- Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2568, Australia.,The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| | - J McKinnon
- The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| | - M Liu
- The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| | - N Hitchick
- San Pathology, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia
| | - N Miller
- San Pathology, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia
| | - C Venturini
- Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia
| | - J Iredell
- Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia
| | - A E Darling
- The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| | - P Roy Chowdury
- The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| | - S P Djordjevic
- The ithree Institute, University of Technology Sydney, NSW 2007, Australia
| |
Collapse
|
13
|
Mendell J, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N, Iammarino M, Alfano L, Vaiea J, Al-Zaidy S, Lewis S, Church K, Shell R, Potter R, Griffin D, Pozsgai E, Hogan M, Rodino-Klapac L. DMD – THERAPY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Iammarino M, Powers B, Miller N, Shannon K, Alfano L, Lowes L. SMA - CLINICAL. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Rodino-Klapac L, Pozsgai E, Lewis S, Griffin D, Meadows A, Lehman K, Church K, Miller N, Iammarino M, Lowes L, Mendell J. LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Powers B, Alcock L, Iammarino M, James M, Miller N, Hilsden H, Shannon K, Lowes L, Alfano L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Mendell J, Shell R, Lehman K, McColly M, Lowes L, Alfano L, Miller N, Iammarino M, Church K, Ogrinc F, Ouyang H, Kernbauer E, Joshi S, Sproule D, Meriggioli M, Feltner D, Al-Zaidy S. SMA – THERAPY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.260] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Alfano L, James M, Miller N, Muni-Lofra R, Iammarino M, Moat D, Powers B, Sodhi J, McCallum M, Shannon K, Eagle M, Mayhew A, Lowes L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Iammarino M, Miller N, Alfano L, Powers B, Shannon K, Connolly A, Waldrop M, Tsao C, Sahenk Z, Flanigan K, Mendell J, Lowes L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Miller N, Iammarino M, Alfano L, Powers B, Shannon K, Nease C, Lehman K, Mendell J, Lowes L. LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Lowes L, Miller N, Iammarino M, Powers B, Shannon K, Alfano L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Dutt R, Miller N, Keiner C, Cotta B, Murphy J, Derweesh I. The impact of delay in time to surgery on outcomes of localized renal cell carcinoma: Analysis based on tumor size. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33204-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
23
|
Dutt R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32709-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
24
|
Patel D, Ghali F, Dutt R, Meagher M, Keiner C, Miller N, Murphy J, Derweesh I. The impact of metastasis location on overall survival among patients with renal cell carcinoma. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33443-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
25
|
Rodriguez JA, Rubio-Gomez H, Roa AA, Miller N, Eckardt PA. Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report. IDCases 2020; 20:e00762. [PMID: 32368493 PMCID: PMC7186517 DOI: 10.1016/j.idcr.2020.e00762] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 04/06/2020] [Indexed: 01/23/2023] Open
Abstract
Coronavirus 2 (SARS-CoV-2) is now considered a pandemic causing Coronavirus disease (COVID-19), multiple fatalities and morbidities which have been associated with it worldwide. We report a severe pneumonia causing acute respiratory distress syndrome due to a coinfection with SARS-COV-2 and Parainfluenza 4 virus in a Hispanic 21 year old male in Florida, USA. The case represents the importance of prompt diagnosis and awareness of the potential co-infection with other respiratory viruses and this novel deadly virus.
Collapse
Affiliation(s)
- Jose A Rodriguez
- Department of Internal Medicine, Memorial Healthcare System, Pembroke Pines, FL, USA
| | - Heysu Rubio-Gomez
- Division of Infectious Disease, Memorial Regional Hospital, Memorial Healthcare System, Hollywood, FL, USA
| | - Alejandra A Roa
- Department of Internal Medicine, Memorial Healthcare System, Pembroke Pines, FL, USA
| | - N Miller
- Microbiology and Molecular Infectious Disease Pathology Consultants of South Broward, LLC, Memorial Healthcare System, Hollywood, FL, USA
| | - Paula A Eckardt
- Division of Infectious Disease, Memorial Regional Hospital, Memorial Healthcare System, Hollywood, FL, USA
| |
Collapse
|
26
|
Hsu PJ, Shi H, Zhu AC, Lu Z, Miller N, Edens BM, Ma YC, He C. The RNA-binding protein FMRP facilitates the nuclear export of N6-methyladenosine-containing mRNAs. J Biol Chem 2019; 294:19889-19895. [PMID: 31753916 PMCID: PMC6937581 DOI: 10.1074/jbc.ac119.010078] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 11/20/2019] [Indexed: 11/06/2022] Open
Abstract
N6-Methyladenosine (m6A) is the most abundant post-transcriptional mRNA modification in eukaryotes and exerts many of its effects on gene expression through reader proteins that bind specifically to m6A-containing transcripts. Fragile X mental retardation protein (FMRP), an RNA-binding protein, has previously been shown to affect the translation of target mRNAs and trafficking of mRNA granules. Loss of function of FMRP causes fragile X syndrome, the most common form of inherited intellectual disability in humans. Using HEK293T cells, siRNA-mediated gene knockdown, cytoplasmic and nuclear fractions, RNA-Seq, and LC-MS/MS analyses, we demonstrate here that FMRP binds directly to a collection of m6A sites on mRNAs. FMRP depletion increased mRNA m6A levels in the nucleus. Moreover, the abundance of FMRP targets in the cytoplasm relative to the nucleus was decreased in Fmr1-KO mice, an effect also observed in highly methylated genes. We conclude that FMRP may affect the nuclear export of m6A-modified RNA targets.
Collapse
Affiliation(s)
- Phillip J Hsu
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois 60637
- Medical Scientist Training Program/Committee on Immunology, University of Chicago, Chicago, Illinois 60637
| | - Hailing Shi
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois 60637
| | - Allen C Zhu
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois 60637
- Medical Scientist Training Program/Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637
| | - Zhike Lu
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois 60637
| | - Nimrod Miller
- Departments of Pediatrics, Neurology and Physiology, Northwestern University Feinberg School of Medicine, Anne and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 60611
| | - Brittany M Edens
- Departments of Pediatrics, Neurology and Physiology, Northwestern University Feinberg School of Medicine, Anne and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 60611
| | - Yongchao C Ma
- Departments of Pediatrics, Neurology and Physiology, Northwestern University Feinberg School of Medicine, Anne and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 60611
| | - Chuan He
- Department of Chemistry and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois 60637
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois 60637
| |
Collapse
|
27
|
Rodino-Klapac L, Pozsgai E, Lewis S, Griffin D, Meadows A, Lehman K, Church K, Miller N, Iammarino M, Lowes L, Mendell J. CLINICAL TRIAL HIGHLIGHTS. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.592] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Alfano L, Miller N, Iammarino M, Lowes L. P.215Utility of functional outcomes in adults with spinal muscular atrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Mah M, Slawinski M, Cripe L, Camino E, Al-Zaidy S, Hassan S, Jackson J, Lowes L, Iammarino M, Miller N, Alfano L, Lehman K, Mendell J, Hor K. DMD CLINICAL. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Mendell J, Shell R, Lehman K, McColly M, Lowes L, Alfano L, Miller N, Iammarino M, Church K, Ogrinc F, Ouyang H, Kernbauer E, Shah S, L'Italien J, Sproule D, Feltner D, Al-Zaidy S. P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Alfano L, Miller N, Iammarino M, Lowes L. P.193The neuromuscular gross motor outcome as an outcome measure in spinal muscular atrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Miller N, Alfano L, Iammarino M, Moore-Clingenpeel M, Tsao C, Waldrop M, Flanigan K, Mendell J, Lowes L. EP.89Clinical trials in young boys and infants with DMD: how do you handle maturation? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Lowes L, Alfano L, Chen D, Nelson L, Miller N, Iammarino M, McColly M, Mendell J, Rust S. P.214Presymptomatic spinal muscular atrophy: reality or myth? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.328] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Waldrop M, Lowes L, Toops J, Alfano L, Miller N, Iammarino M, Kotha K, Paul G, Moore-Clingenpeel M, Tsao C, Noritz G, Shell R, Flanigan K. P.365Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Jackson J, Leslie C, Cotto J, Korth C, Mah M, Hor K, Cripe L, Camino E, Al-Zaidy S, Hassan S, Vannatta K, Lowes L, Iammarino M, Miller N, Alfano L, Lehman K, Mendell J. DMD BRAIN. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Iammarino M, Miller N, Alfano L, Lehman K, Rodino-Klapac L, Mendell J, Lowes L. P.174Establishing divergent phenotypes in limb girdle muscular dystrophies. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Edens BM, Vissers C, Su J, Arumugam S, Xu Z, Shi H, Miller N, Rojas Ringeling F, Ming GL, He C, Song H, Ma YC. FMRP Modulates Neural Differentiation through m 6A-Dependent mRNA Nuclear Export. Cell Rep 2019; 28:845-854.e5. [PMID: 31340148 PMCID: PMC6687293 DOI: 10.1016/j.celrep.2019.06.072] [Citation(s) in RCA: 166] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 04/09/2019] [Accepted: 06/20/2019] [Indexed: 12/21/2022] Open
Abstract
N6-methyladenosine (m6A) modification of mRNA is emerging as a vital mechanism regulating RNA function. Here, we show that fragile X mental retardation protein (FMRP) reads m6A to promote nuclear export of methylated mRNA targets during neural differentiation. Fmr1 knockout (KO) mice show delayed neural progenitor cell cycle progression and extended maintenance of proliferating neural progenitors into postnatal stages, phenocopying methyltransferase Mettl14 conditional KO (cKO) mice that have no m6A modification. RNA-seq and m6A-seq reveal that both Mettl14cKO and Fmr1KO lead to the nuclear retention of m6A-modified FMRP target mRNAs regulating neural differentiation, indicating that both m6A and FMRP are required for the nuclear export of methylated target mRNAs. FMRP preferentially binds m6A-modified RNAs to facilitate their nuclear export through CRM1. The nuclear retention defect can be mitigated by wild-type but not nuclear export-deficient FMRP, establishing a critical role for FMRP in mediating m6A-dependent mRNA nuclear export during neural differentiation.
Collapse
Affiliation(s)
- Brittany M Edens
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Caroline Vissers
- Biochemistry, Molecular and Cellular Biology Training Program, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Jing Su
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Saravanan Arumugam
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Zhaofa Xu
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Han Shi
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Nimrod Miller
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | | | - Guo-Li Ming
- Department of Neuroscience and Mahoney Institute for Neuroscience, Department of Cell and Developmental Biology, Institute for Regeneration, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Chuan He
- Departments of Chemistry and Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, USA
| | - Hongjun Song
- Department of Neuroscience and Mahoney Institute for Neuroscience, Department of Cell and Developmental Biology, Institute for Regeneration, University of Pennsylvania, Philadelphia, PA 19104, USA.
| | - Yongchao C Ma
- Departments of Pediatrics, Neurology, and Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
| |
Collapse
|
38
|
Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N, Zhang C, Visswanathan R, Boras B, VanArsdale T, White MA. Abstract P6-20-06: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-20-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N, Zhang C, Visswanathan R, Boras B, VanArsdale T, White MA. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-20-06.
Collapse
Affiliation(s)
- S Dann
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - J Chionis
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - K Eisele
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - Q Zhang
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - C Liu
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - J Yuan
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - N Miller
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - B Murray
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - M Xu
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - J Solowiej
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - P Wei
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - S Weinrich
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - S Sutton
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - D Behenna
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - S Ninkovic
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - R Hoffman
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - K Freeman-Cook
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - B Jessen
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - N Huser
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - C Zhang
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - R Visswanathan
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - B Boras
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - T VanArsdale
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| | - MA White
- Pfizer Oncology Research Division, La Jolla, CA; Pfizer Medicinal Sciences, La Jolla, CA
| |
Collapse
|
39
|
Jie X, Xiao T, Yao B, Gonzalez-Cortes S, Wang J, Fang Y, Miller N, AlMegren H, Dilworth J, Edwards P. On the performance optimisation of Fe catalysts in the microwave - assisted H2 production by the dehydrogenation of hexadecane. Catal Today 2018. [DOI: 10.1016/j.cattod.2018.03.036] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Flanigan K, Chicoine L, Cheatham J, Cheatham S, Simmons T, Lowes L, Iammarino M, Miller N, Alfano L, Rinaldi F, Waldrop M, Zygmunt D, Xu R, Martin P. DMD CLINICAL THERAPIES II. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Miller N, Lowes L, James M, Alfano L, Mayhew A, Maron E, Gee R, Harman M, Duong T, Vandervelde B, Siener C, Thiele S, Mendez B, Canal A, Sakamoto C, Holsten S, Pedrosa Belmonte I, Semplicini C, Straub V. LIMB-GIRDLE MUSCULAR DYSTROPHY I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Lowes L, Alfano L, Iammarino M, Miller N, Menier M, Cardenas J, Sproule D, Nagendran S, Al-Zaidy S, Mendell J. SMA THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Alfano L, Miller N, Iammarino M, Berry K, Moore-Clingenpeel M, Dugan M, Al-Zaidy S, Tsao C, Rodino-Klapac L, Waldrop M, Flanigan K, Mendell J, Lowes L. DUCHENNE MUSCULAR DYSTROPHY - PHYSIOTHERAPY. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Alfano L, Miller N, Iammarino M, Moore-Clingenpeel M, Lowes S, Dugan M, Waldrop M, Flanigan K, Noritz G, Tsao C, Al Zaidy S, Kissel J, Lowes L. SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
McVeigh U, McVeigh T, Miller N, Morris D, Kerin M. PO-343 Targeted resequencing identifies novel and ultra-rare high-impact variants in breast cancer susceptibility genes in an Irish population. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
46
|
Sexton K, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie B, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN. A89 THE IBD SYMPTOM INVENTORY: MEASUREMENT CHARACTERISTICS AND VALIDITY IN A CLINIC SAMPLE. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy008.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Sexton
- University of Manitoba, Winnipeg, MB, Canada
| | - J R Walker
- University of Manitoba, Winnipeg, MB, Canada
| | | | - L A Graff
- University of Manitoba, Winnipeg, MB, Canada
| | - C Haviva
- University of Manitoba, Winnipeg, MB, Canada
| | - B Beatie
- University of Manitoba, Winnipeg, MB, Canada
| | - S K Petty
- University of Manitoba, Winnipeg, MB, Canada
| | | | - H Singh
- University of Manitoba, Winnipeg, MB, Canada
| | - N Miller
- University of Manitoba, Winnipeg, MB, Canada
| | | |
Collapse
|
47
|
Witges K, Targownik LE, Haviva C, Sexton K, Walker JR, Graff LA, Lix L, Miller N, Bernstein CN. A113 WHAT IS A FLARE OF IBD? THE MANITOBA LIVING WITH IBD STUDY. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy008.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Witges
- University of Manitoba, Winnipeg, MB, Canada
| | | | - C Haviva
- University of Manitoba, Winnipeg, MB, Canada
| | - K Sexton
- University of Manitoba, Winnipeg, MB, Canada
| | - J R Walker
- University of Manitoba, Winnipeg, MB, Canada
| | - L A Graff
- Clinical Health Psychology, University of Manitoba, Winnipeg, MB, Canada
| | - L Lix
- University of Manitoba, Winnipeg, MB, Canada
| | - N Miller
- University of Manitoba, Winnipeg, MB, Canada
| | | |
Collapse
|
48
|
Lalani N, Paszat L, Sutradhar R, Gu S, Fong C, Nofech-Mozes S, Hanna W, Tuck A, Youngson B, Miller N, Done SJ, Chang MC, Sengupta S, Elavathil L, Jani PA, Bonin M, Rakovitch E. Abstract P4-15-05: The presence of one or multiple foci of microinvasion is not associated with an increased risk of local recurrence in women with ductal carcinoma in situ treated with breast conserving therapy. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-15-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Ductal Carcinoma in Situ (DCIS) is a non-invasive breast cancer often treated with breast-conserving surgery (BCS) with or without radiotherapy (RT). It is unclear if the presence of microinvasion (MI) (invasion ≤1mm) is associated with an increased risk of LR (DCIS or invasive) or invasive LR compared to women with pure DCIS. In addition, the impact of multiple foci (>2) of MI compared to pure DCIS is also unknown; therefore, it is unclear if some women with MI require more aggressive treatment. We evaluated the impact of the presence of MI and the number of foci of MI on the risks of any LR and invasive LR in a population of women with DCIS with and without MI treated with BCS.
Methods: The cohort includes all women diagnosed with pure DCIS or DCIS with MI in Ontario from 1994-2003 treated with BCS +/- RT. All cases had systematic pathology review to confirm the presence and number of foci of MI. Treatment and outcomes were ascertained through administrative databases and validated by chart review. Cox proportional hazards model was used to evaluate the impact of MI and the number of foci of MI (1 vs >2 foci) on the development of any LR and invasive LR compared to cases with pure DCIS. The 10-yr local recurrence-free survival (LRFS) and invasive LRFS rates were calculated using the Kaplan-Meier approach with differences compared using the log-rank test.
Results: The population cohort includes 2,988 women with DCIS treated by BCS (N=2,721 pure DCIS, N= 267 DCIS with MI). Median follow-up (12 years; p=.23) and median age at diagnosis (58 years; p=.17) were similar in both groups. RT was given in 58% of cases with MI and 51% of cases with pure DCIS (p=.03). Hormonal therapy was utilized in 7.1% of women with MI and 5.3% of women with pure DCIS (p=.22). LR developed in 59 (22.1%) cases with MI and 530 (19.6%) cases of pure DCIS. Women with MI were more likely to have high nuclear grade (p<.001), and larger tumor size (p<.001) compared to those without MI. On multivariable analyses adjusted for age, the presence of 1 focus of MI(HR=.92, 95% CI: .64-1.33) or ≥2 foci of MI (HR=1.26, 95% CI: .85-1.85) was not associated with an increased risk of any LR compared to cases with pure DCIS. Factors associated with any LR were age <50 years at diagnosis, RT, multifocality and high nuclear grade. The presence of 1 focus of MI (HR=.86, 95% CI: .52-1.40) or > 2 foci of MI (HR=1.45, 95% CI: .90-2.32) was also not associated with an increased risk of invasive LR compared to cases of pure DCIS. Among women treated with BCS alone, the 10 year LRFS rates were 80%, 75% and 73% for women with pure DCIS, 1 focus, >2 foci of MI (p=.10). The invasive LRFS rates were 89%, 91% and 85% (p=.26). Among women treated with BCS+RT, the 10 year LRFS rates were 87%, 88% and 80% (p=0.32) for women with pure DCIS, 1 focus or ≥2 foci of MI. The invasive LRFS rates were 93%, 90% and 86% (p=.44). There was no interaction between the presence of MI and RT.
Conclusions: Women with DCIS with one or multiple foci of microinvasion (<1mm) treated by breast conserving therapy do not have an increased risk of LR or invasive LR compared to women with pure DCIS.
Citation Format: Lalani N, Paszat L, Sutradhar R, Gu S, Fong C, Nofech-Mozes S, Hanna W, Tuck A, Youngson B, Miller N, Done SJ, Chang MC, Sengupta S, Elavathil L, Jani PA, Bonin M, Rakovitch E. The presence of one or multiple foci of microinvasion is not associated with an increased risk of local recurrence in women with ductal carcinoma in situ treated with breast conserving therapy [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-15-05.
Collapse
Affiliation(s)
- N Lalani
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - L Paszat
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - R Sutradhar
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - S Gu
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - C Fong
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - S Nofech-Mozes
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - W Hanna
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - A Tuck
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - B Youngson
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - N Miller
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - SJ Done
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - MC Chang
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - S Sengupta
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - L Elavathil
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - PA Jani
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - M Bonin
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| | - E Rakovitch
- University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; London Health Sciences Centre, London, ON, Canada; University Health Network, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada
| |
Collapse
|
49
|
Lalani N, Paszat L, Nofech-Mozes S, Sutradhar R, Gu S, Hanna W, Fong C, Miller N, Youngson B, Done SJ, Tuck A, Chang MC, Sengupta S, Jani PA, Bonin M, Rakovitch E. Abstract P2-12-02: Is breast-conserving therapy effective in women with large ductal carcinoma in situ (DCIS) lesions? A population-based analysis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Most women diagnosed with DCIS will be treated by breast-conserving surgery (BCS) with or without radiotherapy (RT). Data on outcomes following breast-conserving therapy are predominantly based on women with small (<25mm) lesions. The paucity of data on outcomes of women with larger (>40mm) DCIS lesions leads to uncertainty of the appropriateness of breast-conserving therapy for women with larger lesions. Specifically, it is unclear if women with large tumors experience higher risks of local recurrence (LR) and invasive LR after BCS+/-RT that would preclude recommendations of breast-conserving therapy. We report the outcomes and evaluate the impact of large tumor size (>40mm) on recurrence risk in a population of women with pure DCIS treated by BCS alone or with RT.
Methods: The cohort includes all women diagnosed with DCIS in Ontario from 1994-2003 treated with BCS +/- RT; 82% had pathology review. Treatment and outcomes were ascertained through administrative databases and validated by chart review. Cox proportional hazards model was used to evaluate the impact of tumor size (≤10mm,11-25mm, 26-39mm, ≥40mm) on the development of any LR (DCIS or invasive) and invasive LR. The 10 and 15-year LR-free survival (LRFS) and invasive LRFS rates were calculated using the Kaplan-Meier method with differences compared using the log-rank test.
Results: The cohort includes 3262 women with DCIS treated by BCS (N=1635 had RT). Median age at diagnosis was 59 years (IQR 50-68 years). Median follow-up was 13 years (IQR 8-15 years). Distribution of tumor size: 707 (22%) ≤10mm, 524 (16%) 11-25mm, 107 (3%) 26-39mm, 84 (3%) ≥40mm, unable to determine in 1840 (56%). Women with lesions ≥ 40mm were more likely to be ≤50 years of age at diagnosis (p=.02), have high nuclear grade (p<.001), multifocality (p<.001), and positive margins (p<.001) compared to women with smaller lesions. On multivariable analyses adjusted for age and year of diagnosis, tumor size ≥40mm was significantly associated with an increased risk of LR compared to size ≤10mm (HR=2.5, 95%CI:1.64-3.81). Other factors associated with LR were age <50 years (p<.001), omission of RT (p<.001), high nuclear grade (p=.002), and multifocality (p=.0008). Tumor size ≥40mm was not significantly associated with an increased risk of invasive LR (HR=1.68, 95%CI:.94-3.04). Women with tumour size ≥40mm treated with BCS alone had lower 10 and 15 year LRFS (53% and 41%) and invasive LRFS rates (78% and 75%) compared to women with smaller lesions. However, women with larger lesions treated with RT had significantly higher LRFS and invasive LRFS rates
Outcomes by tumour size for women with DCIS treated with BCS with or without RT ≤10mm N=70711-25mm N=52426-39mm N=107≥40mm N=84p-valueBCS AloneLRFS (%) 10 yr85797053<0.001 15 yr81746741 Invasive LRFS (%) 10 yr928786780.03 15 yr89838375 BCS + RTLRFS (%) 10 yr928874850.01 15 yr86847079 Invasive LRFS (%) 10 yr959492910.27 15 yr90918789
. There was a significant interaction between tumor size ≥40mm and RT (p=.02).
Conclusions: Women with DCIS lesions ≥40mm treated by BCS alone experience significantly higher risks of LR and invasive LR compared to smaller lesions but this risk can be mitigated with the addition of RT.
Citation Format: Lalani N, Paszat L, Nofech-Mozes S, Sutradhar R, Gu S, Hanna W, Fong C, Miller N, Youngson B, Done SJ, Tuck A, Chang MC, Sengupta S, Jani PA, Bonin M, Rakovitch E. Is breast-conserving therapy effective in women with large ductal carcinoma in situ (DCIS) lesions? A population-based analysis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-12-02.
Collapse
Affiliation(s)
- N Lalani
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - L Paszat
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - S Nofech-Mozes
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - R Sutradhar
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - S Gu
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - W Hanna
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - C Fong
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - N Miller
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - B Youngson
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - SJ Done
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - A Tuck
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - MC Chang
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - S Sengupta
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - PA Jani
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - M Bonin
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| | - E Rakovitch
- University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; Univeristy Health Network, Toronto, ON, Canada; London Health Sciences Centre, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Queen's University, Kingston, ON, Canada; Thunder Bay Regional Health Sciences Centre & Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Sudbury Regional Hospital, Sudbury, ON, Canada
| |
Collapse
|
50
|
McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill DS, Weidhaas JB, Kerin MJ, Lowery AJ. Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. Endocr Connect 2017; 6:614-624. [PMID: 28899898 PMCID: PMC5640569 DOI: 10.1530/ec-17-0196] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 09/12/2017] [Indexed: 01/05/2023]
Abstract
INTRODUCTION MicroRNAs (miRNAs) are small noncoding RNA molecules that exert post-transcriptional effects on gene expression by binding with cis-regulatory regions in target messenger RNA (mRNA). Polymorphisms in genes encoding miRNAs or in miRNA-mRNA binding sites confer deleterious epigenetic effects on cancer risk. miR-146a has a role in inflammation and may have a role as a tumour suppressor. The polymorphism rs2910164 in the MIR146A gene encoding pre-miR-146a has been implicated in several inflammatory pathologies, including cancers of the breast and thyroid, although evidence for the associations has been conflicting in different populations. We aimed to further investigate the association of this variant with these two cancers in an Irish cohort. METHODS The study group comprised patients with breast cancer (BC), patients with differentiated thyroid cancer (DTC) and unaffected controls. Germline DNA was extracted from blood or from saliva collected using the DNA Genotek Oragene 575 collection kit, using crystallisation precipitation, and genotyped using TaqMan-based PCR. Data were analysed using SPSS, v22. RESULTS The total study group included 1516 participants. This comprised 1386 Irish participants; 724 unaffected individuals (controls), 523 patients with breast cancer (BC), 136 patients with differentiated thyroid cancer (DTC) and three patients with dual primary breast and thyroid cancer. An additional cohort of 130 patients with DTC from the South of France was also genotyped for the variant. The variant was detected with a minor allele frequency (MAF) of 0.19 in controls, 0.22 in BC and 0.27 and 0.26 in DTC cases from Ireland and France, respectively. The variant was not significantly associated with BC (per allele odds ratio = 1.20 (0.98-1.46), P = 0.07), but was associated with DTC in Irish patients (per allele OR = 1.59 (1.18-2.14), P = 0.002). CONCLUSION The rs2910164 variant in MIR146A is significantly associated with DTC, but is not significantly associated with BC in this cohort.
Collapse
Affiliation(s)
- T P McVeigh
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - R J Mulligan
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - U M McVeigh
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - P W Owens
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - N Miller
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - M Bell
- Department of EndocrinologySchool of Medicine, NUI Galway, Galway, Ireland
| | - F Sebag
- Department of Endocrine Surgery Centre hospitalo-universitaire de La ConceptionAssistance Publique Hôpitaux de Marseille, Marseille, France
- Aix-Marseille UniversitéFaculté de Médecine, Marseille, France
| | - C Guerin
- Department of Endocrine Surgery Centre hospitalo-universitaire de La ConceptionAssistance Publique Hôpitaux de Marseille, Marseille, France
- Aix-Marseille UniversitéFaculté de Médecine, Marseille, France
| | - D S Quill
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - J B Weidhaas
- David Geffen School of MedicineUniversity of California, Los Angeles, USA
| | - M J Kerin
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| | - A J Lowery
- Discipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland
| |
Collapse
|